Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial

被引：0
|
作者：
Boehm, M. [1 ]
Anker, S. D. [2 ]
Mahfoud, F. [1 ]
Filippatos, G. [3 ]
Ferreira, J. P. [4 ]
Pocock, S. J. [5 ]
Brueckmann, M. [6 ]
Linetzky, B. [7 ]
Schueler, E. [8 ]
Wanner, C. [9 ]
Zannad, F. [4 ]
Packer, M. [10 ]
Butler, J. [11 ]
机构：
[1] Univ Hosp Saarland, Clin Internal Med Cardiol Angiol & Intens Care Me, Homburg, Germany
[2] Charite Univ Med Berlin, Dept Cardiol CVK, Berlin, Germany
[3] Natl & Kapodistrian Univ Athens, Athens Univ Hosp, Sch Med, Athens, Greece
[4] Univ Lorraine, Nancy, France
[5] London Sch Hyg & Trop Med, London, England
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Eli Lilly Interamer Inc, Buenos Aires, DF, Argentina
[8] mainanalyt GmbH, Sulzbach, Germany
[9] Wuerzburg Univ Clin, Wurzburg, Germany
[10] Baylor Univ Med Ctr, Dallas, TX USA
[11] Baylor Scott & White Hlth, Dallas, TX USA
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：983 / 983
页数：1
相关论文
共 50 条
  • [31] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao P.
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans-Peter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure-Valenzuela, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Carson, Peter
    Lam, Carolyn Su Ping
    Marx, Nikolaus
    Zeller, Cordula
    Sattar, Naveed
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16): : 1451 - 1461
  • [32] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Gollop, N. D.
    Iwata, T.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 131 - 132
  • [33] Design and rationale of the EMPEROR trials of empagliflozin 10mg once daily in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)
    Anker, S. D.
    Zannad, F.
    Butler, J.
    Filippatos, G.
    Schnee, J.
    Zeller, C.
    Pocock, S.
    George, J. T.
    Brueckmann, M.
    Packer, M.
    DIABETIC MEDICINE, 2019, 36 : 47 - 47
  • [34] Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
    Stefan D. Anker
    Javed Butler
    Muhammad Shariq Usman
    Gerasimos Filippatos
    João Pedro Ferreira
    Edimar Bocchi
    Michael Böhm
    Hans Pieter Brunner-La Rocca
    Dong-Ju Choi
    Vijay Chopra
    Eduardo Chuquiure
    Nadia Giannetti
    Juan Esteban Gomez-Mesa
    Stefan Janssens
    James L. Januzzi
    José R. González-Juanatey
    Bela Merkely
    Stephen J. Nicholls
    Sergio V. Perrone
    Ileana L. Piña
    Piotr Ponikowski
    Michele Senni
    David Sim
    Jindrich Spinar
    Iain Squire
    Stefano Taddei
    Hiroyuki Tsutsui
    Subodh Verma
    Dragos Vinereanu
    Jian Zhang
    Tomoko Iwata
    Janet M. Schnee
    Martina Brueckmann
    Stuart J. Pocock
    Faiez Zannad
    Nature Medicine, 2022, 28 : 2512 - 2520
  • [35] Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
    Anker, Stefan D.
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Bocchi, Edimar
    Bohm, Michael
    Brunner-La Rocca, Hans Pieter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Iwata, Tomoko
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    NATURE MEDICINE, 2022, 28 (12) : 2512 - +
  • [36] Empagliflozin benefits in patients with heart failure and preserved ejection fraction
    Anker, Stefan D.
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans Pieter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure, Eduardo
    Giannetti, Nadia
    Esteban Gomez-Mesa, Juan
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Iwata, Tomoko
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    NATURE MEDICINE, 2022, 28 (12) : 2480 - 2481
  • [37] Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
    Fauchier, Laurent
    Lamblin, Nicolas
    Tardu, Jean
    Bellier, Lucile
    Groyer, Harinala
    Ittah, Deborah
    Chollet, Julien
    Linden, Stephan
    Levy, Pierre
    PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 19 - 30
  • [38] Impact of empagliflozin on insulin use in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes: sub-analysis from EMPEROR-Preserved trial
    Butler, J.
    Green, J. B.
    Rosenstock, J.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S285 - S286
  • [39] Empagliflozin benefits in patients with heart failure and preserved ejection fraction
    Nature Medicine, 2022, 28 : 2480 - 2481
  • [40] Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
    Laurent Fauchier
    Nicolas Lamblin
    Jean Tardu
    Lucile Bellier
    Harinala Groyer
    Deborah Ittah
    Julien Chollet
    Stephan Linden
    Pierre Levy
    PharmacoEconomics - Open, 2024, 8 : 19 - 30
12345